| Literature DB >> 33802424 |
Chikashi Watase1, Sho Shiino1, Tatsunori Shimoi2, Emi Noguchi2, Tomoya Kaneda3, Yusuke Yamamoto4, Kan Yonemori2, Shin Takayama1, Akihiko Suto1.
Abstract
Breast cancer is the second most common origin of brain metastasis after lung cancer. Brain metastasis in breast cancer is commonly found in patients with advanced course disease and has a poor prognosis because the blood-brain barrier is thought to be a major obstacle to the delivery of many drugs in the central nervous system. Therefore, local treatments including surgery, stereotactic radiation therapy, and whole-brain radiation therapy are currently considered the gold standard treatments. Meanwhile, new targeted therapies based on subtype have recently been developed. Some drugs can exceed the blood-brain barrier and enter the central nervous system. New technology for early detection and personalized medicine for metastasis are warranted. In this review, we summarize the historical overview of treatment with a focus on local treatment, the latest drug treatment strategies, and future perspectives using novel therapeutic agents for breast cancer patients with brain metastasis, including ongoing clinical trials.Entities:
Keywords: BRCA gene mutation; CDK4/6 inhibitor; blood–brain barrier; central nervous system; immune checkpoint inhibitor; molecular-targeted therapy; neurosurgery; review; stereotactic radiosurgery (SRS); tyrosine kinase inhibitor; whole brain radiation therapy (WBRT)
Year: 2021 PMID: 33802424 PMCID: PMC7959316 DOI: 10.3390/cancers13051078
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639